Anti-RGS8 paraneoplastic cerebellar ataxia is preferentially associated with a particular subtype of Hodgkin's lymphoma.

Anti-RGS8 antibodies B-cell lymphoma Cerebellar ataxia Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) Onconeural antigen Paraneoplastic neurological syndrome

Journal

Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161

Informations de publication

Date de publication:
29 Aug 2024
Historique:
received: 04 07 2024
accepted: 28 07 2024
revised: 26 07 2024
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 29 8 2024
Statut: aheadofprint

Résumé

Ataxia with anti-regulator of G-protein signaling 8 autoantibodies (RGS8-Abs) is an autoimmune disease recently described in four patients. The present study aimed to identify other patients with RGS8-Abs, describe their clinical features, including the link between RGS8-related autoimmune cerebellar ataxia (ACA) and cancer. Patients with RGS8-Abs were identified retrospectively in the biological collections of the French Reference Center for Paraneoplastic Neurological Syndrome and the University of California San Francisco Center for Encephalitis and Meningitis. Clinical data were collected, and cerebrospinal fluid, serum, and tumor pathological samples were retrieved to characterize the autoantibodies and the associated malignancies. Only three patients with RGS8-Abs were identified. All of them presented with a pure cerebellar ataxia of mild to severe course, unresponsive to current immunotherapy regimens for ACA. Two patients presented with a Hodgkin lymphoma of the rare specific subtype called nodular lymphocyte-predominant Hodgkin lymphoma, with very mild extension. Autoantibodies detected in all patients enriched the same epitope on the RGS8 protein, which is an intracellular protein physiologically expressed in Purkinje cells but also ectopically expressed specifically in lymphoma cells of patients with RGS8-related ACA. The present results and those of the four cases previously described suggest that RGS8-Abs define a new paraneoplastic neurological syndrome of extreme rarity found mostly in middle-aged males that associates pure cerebellar ataxia and a particular lymphoma specifically expressing the RGS8 antigen. As in other paraneoplastic ACA with intracellular antigen, the disease course is severe, and patients tend to exhibit a poor response to immune therapy.

Identifiants

pubmed: 39207522
doi: 10.1007/s00415-024-12618-4
pii: 10.1007/s00415-024-12618-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Agence Nationale de la Recherche
ID : ANR-18-RHUS-0012
Organisme : National Institute of Mental Health and Neurosciences
ID : R01MH122471
Organisme : National Institute of Mental Health and Neurosciences
ID : R25MH060482

Informations de copyright

© 2024. The Author(s).

Références

Miske R, Scharf M, Stark P et al (2021) Autoantibodies against the purkinje cell protein RGS8 in paraneoplastic cerebellar syndrome. Neurol Neuroimmunol Neuroinflamm 8:e987. https://doi.org/10.1212/NXI.0000000000000987
doi: 10.1212/NXI.0000000000000987 pubmed: 33782191 pmcid: 8009278
McKeon A, Lesnick C, Vorasoot N et al (2023) Utility of protein microarrays for detection of classified and novel antibodies in autoimmune neurologic disease. Neurol Neuroimmunol Neuroinflamm 10:e200145. https://doi.org/10.1212/NXI.0000000000200145
doi: 10.1212/NXI.0000000000200145 pubmed: 37550073 pmcid: 10406426
Do L-D, Chanson E, Desestret V et al (2017) Characteristics in limbic encephalitis with anti–adenylate kinase 5 autoantibodies. Neurology 88:514–524
doi: 10.1212/WNL.0000000000003586 pubmed: 28062719
Do LD, Gupton SL, Tanji K et al (2019) TRIM9 and TRIM67 are new targets in paraneoplastic cerebellar degeneration. Cerebellum 18:245–254
doi: 10.1007/s12311-018-0987-5 pubmed: 30350014 pmcid: 6445697
Peter E, Hannoun S, Muñiz-Castrillo S et al (2022) Cerebellar ataxia with anti-DNER antibodies: outcomes and immunologic features. Neurol-Neuroimmunol Neuroinflamm 9(5):e200018
doi: 10.1212/NXI.0000000000200018 pubmed: 35940913 pmcid: 9359625
Larman HB, Zhao Z, Laserson U et al (2011) Autoantigen discovery with a synthetic human peptidome. Nat Biotechnol 29:535–541
doi: 10.1038/nbt.1856 pubmed: 21602805 pmcid: 4169279
Mandel-Brehm C, Dubey D, Kryzer TJ et al (2019) Kelch-like protein 11 antibodies in seminoma-associated paraneoplastic encephalitis. N Engl J Med 381:47–54
doi: 10.1056/NEJMoa1816721 pubmed: 31269365 pmcid: 6800027
Bartley CM, Ngo TT, Do LD et al (2023) Detection of high-risk paraneoplastic antibodies against TRIM9 and TRIM67 proteins. Ann Neurol 94(6):1086–1101
doi: 10.1002/ana.26776 pubmed: 37632288
Swerdlow SH, Campo E, Pileri SA et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127:2375–2390. https://doi.org/10.1182/blood-2016-01-643569
doi: 10.1182/blood-2016-01-643569 pubmed: 26980727 pmcid: 4874220
Carbone PP, Kaplan HS, Musshoff K et al (1971) Report of the committee on Hodgkin’s disease staging classification. Cancer Res 31:1860–1861
pubmed: 5121694
Graus F, Vogrig A, Muñiz-Castrillo S et al (2021) Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflammation 8:e1014. https://doi.org/10.1212/NXI.0000000000001014
doi: 10.1212/NXI.0000000000001014
Eichenauer DA, Engert A (2017) Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management. Hematology 2017:324–328. https://doi.org/10.1182/asheducation-2017.1.324
doi: 10.1182/asheducation-2017.1.324 pubmed: 29222274 pmcid: 6142570
Smith LB (2010) Nodular lymphocyte predominant hodgkin lymphoma: diagnostic pearls and pitfalls. Arch Pathol Lab Med 134:1434–1439. https://doi.org/10.5858/2010-0207-OA.1
doi: 10.5858/2010-0207-OA.1 pubmed: 20923296
Small M, Treilleux I, Couillault C et al (2018) Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. Acta Neuropathol 135:569–579. https://doi.org/10.1007/s00401-017-1802-y
doi: 10.1007/s00401-017-1802-y pubmed: 29299667
Peter E, Treilleux I, Wucher V et al (2022) Immune and genetic signatures of breast carcinomas triggering anti-Yo–associated paraneoplastic cerebellar degeneration. Neurol-Neuroimmunol Neuroinflammation 9(5):e200015
doi: 10.1212/NXI.0000000000200015
Peterson K, Rosenblum M, Kotanides H, Posner J (1992) Paraneoplastic cerebellar degeneration: IA clinical analysis of 55 anti-Yo antibody-positive patients. Neurology 42:1931–1931
doi: 10.1212/WNL.42.10.1931 pubmed: 1407575
Alamowitch S, Graus F, Uchuya M et al (1997) Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain J Neurol 120:923–928
doi: 10.1093/brain/120.6.923
Wu Q-W, Kapfhammer JP (2021) Modulation of increased mGluR1 Signaling by RGS8 protects Purkinje cells from dendritic reduction and could be a common mechanism in diverse forms of spinocerebellar ataxia. Front Cell Dev Biol 8:569889
doi: 10.3389/fcell.2020.569889 pubmed: 33553137 pmcid: 7858651
Spatola M, Petit Pedrol M, Maudes E et al (2020) Clinical features, prognostic factors, and antibody effects in anti-mGluR1 encephalitis. Neurology 95:e3012. https://doi.org/10.1212/WNL.0000000000010854
doi: 10.1212/WNL.0000000000010854 pubmed: 32928978 pmcid: 7734921
Sethakorn N, Dulin NO (2013) RGS expression in cancer: oncomining the cancer microarray data. J Recept Signal Transduct 33:166–171
doi: 10.3109/10799893.2013.773450

Auteurs

Elise Peter (E)

French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
MeLiS - UCBL - CNRS UMR 5284 - INSERM U1314, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Nicolas Lundahl Ciano-Petersen (NL)

Biomedical Research Institute of Málaga (IBIMA) and Platform of Nanomedicine (BIONAND), Málaga, Spain.

Le-Duy Do (LD)

French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
MeLiS - UCBL - CNRS UMR 5284 - INSERM U1314, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Jimmy Perrot (J)

Hospices Civils de Lyon, Service d'Anatomie Pathologique, Centre Hospitalier Lyon Sud, Lyon, France.

Thomas Ngo (T)

Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.

John Pluvinage (J)

Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.

Christopher M Bartley (CM)

Weill Institute for Neurosciences, Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, San Francisco, CA, USA.

Kelsey C Zorn (KC)

Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.

Ramona Miske (R)

Unit for Experimental Immunology, Affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Luebeck, Germany.

Madeleine Scharf (M)

Unit for Experimental Immunology, Affiliated to EUROIMMUN Medizinische Labordiagnostika AG, Luebeck, Germany.

Macarena Villagrán-García (M)

French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
MeLiS - UCBL - CNRS UMR 5284 - INSERM U1314, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Antonio Farina (A)

French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
MeLiS - UCBL - CNRS UMR 5284 - INSERM U1314, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Véronique Rogemond (V)

French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
MeLiS - UCBL - CNRS UMR 5284 - INSERM U1314, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Jean-Christophe Antoine (JC)

French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
Université Jean Monnet, Saint-Etienne, France.
Département de Neurologie, Centre Hospitalier Universitaire de Saint Etienne, Saint-Etienne, France.

Christine Tranchant (C)

Service de Neurologie, Hôpital de Hautepierre, Strasbourg, France.
Faculté de Médecine, Fédération de Médecine Translationnelle, Strasbourg, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Illkirch, France.

Valérie Dubois (V)

Laboratoire d'étude du HLA, Etablissement Français du Sang Auvergne-Rhône-Alpes, Lyon, France.

Joseph L DeRisi (JL)

Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA.
Chan Zuckerberg Biohub SF, San Francisco, CA, USA.

Samuel J Pleasure (SJ)

Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.

Michael R Wilson (MR)

Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.

Jeffrey M Gelfand (JM)

Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.

Alexandra Traverse-Glehen (A)

Hospices Civils de Lyon, Service d'Anatomie Pathologique, Centre Hospitalier Lyon Sud, Lyon, France.

Jérôme Honnorat (J)

French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France.
MeLiS - UCBL - CNRS UMR 5284 - INSERM U1314, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Virginie Desestret (V)

French Reference Center on Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, Hôpital Neurologique, Bron, France. Virginie.desestret@chu-lyon.fr.
MeLiS - UCBL - CNRS UMR 5284 - INSERM U1314, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France. Virginie.desestret@chu-lyon.fr.

Classifications MeSH